Editas Medicine Inc EDIT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EDIT is a good fit for your portfolio.
News
-
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
-
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
-
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
-
Editas Medicine to Participate in Upcoming Investor Conferences
-
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals — Update
-
Vertex's stock heads for all-time high as non-opioid painkiller shows promise
-
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
-
Editas Medicine Gets Orphan Drug Designation for EDIT-301
Trading Information
- Previous Close Price
- $5.49
- Day Range
- $5.38–5.79
- 52-Week Range
- $5.29–11.91
- Bid/Ask
- $5.56 / $5.97
- Market Cap
- $460.51 Mil
- Volume/Avg
- 1.7 Mil / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.40
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 226
- Website
- https://www.editasmedicine.com
Comparables
Valuation
|
Metric
|
EDIT
|
NTLA
|
CRSP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.30 | 1.93 | 2.39 |
Price/Sales | 5.40 | 53.47 | 12.02 |
Price/Cash Flow | — | — | — |
Price/Earnings
EDIT
NTLA
CRSP
Financial Strength
|
Metric
|
EDIT
|
NTLA
|
CRSP
|
|---|---|---|---|
Quick Ratio | 5.27 | 8.23 | 17.41 |
Current Ratio | 5.39 | 8.67 | 17.54 |
Interest Coverage | — | — | — |
Quick Ratio
EDIT
NTLA
CRSP
Profitability
|
Metric
|
EDIT
|
NTLA
|
CRSP
|
|---|---|---|---|
Return on Assets (Normalized) | −26.43% | −25.49% | −3.61% |
Return on Equity (Normalized) | −37.32% | −30.88% | −4.34% |
Return on Invested Capital (Normalized) | −38.19% | −31.84% | −3.83% |
Return on Assets
EDIT
NTLA
CRSP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mdkbfntrlg | Vfln | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kjpmhgchy | Rppmyg | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yfkcdxd | Dnqbzl | $98.8 Bil | |
MRNA
| Moderna Inc | Fbqnmyn | Qwr | $38.8 Bil | |
ARGX
| argenx SE ADR | Rnyqqfvg | Vwdq | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Xpjtpgvb | Tdsb | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xxngxkmc | Rhcljry | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gccppjfk | Gwcxxlp | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Crfmccgd | Kfstvx | $12.4 Bil | |
INCY
| Incyte Corp | Rysshrgkx | Gtzmsn | $11.9 Bil |